ABC | Volume 114, Nº5, May 2020

Statement Brazilian Cardiology Society Statement for Management of Pregnancy and Family Planning in Women with Heart Disease – 2020 Arq Bras Cardiol. 2020; 114(5):849-942 40. Wang PI, Chong ST, Kielar AZ, Kelly AM, Knoepp UD, Mazza MB, et al. Imaging of pregnant and lactating patients: part 1, evidence-based review and recommendations . AJR Am J Roentgenol. 2012;198(4):778-84. 41. Brent RL. The effect of embrionic and fetal exposure to x-ray, microwaves, and ultrasond: counseling the pregnant and nonpregnant patient about these risks. Semin Oncol. 1989;16(5):347-68. 42. Tirada N, Dreizin D, Khati NJ, Akin EA, Zeman RK. Imaging pregnant and lactating patients Radiographics. 2015;35(6):1751-65. 43. Plaut S. Radiation protection in the X-ray department. London : Butterworth &Heinemann; 1993. p.157. 44. Johnson PT, Deshmukh S, Mahesh M, Grant KL, Fishman EK. CT dose radiation applications: available tools on the latest generation of CT scanners. J Am Coll Radiol. 2013;10(1):37-41. 45. CollettiPM.PET-CT inthepregnantpatient. ImageWisely.[Internet]. [Cited in 2014 Jan 14]. Available from: https://www.imagewisely.org/~/media/ ImageWisely-Files/NuclMed/PETCT-inthe_Pregnant-Patient.pdf 46. Wang PI, Chong ST, Kielar AZ, Kelly AM, Knoepp UD, Mazza MB, et al. Imaging of pregnant and lactating patients II Evidence-based review and recommendations. AJR Am J Roentgenol. 2012;198(4):785-92. 47. Ray JG, Vermeulen MJ, Bharatha A, MontaneraWJ, Park AL. Associations between MRI exposure during pregnancy and fetal and chidhood outcomes. JAMA. 2016;316(9):952-61. 48. PieperPG.UsedeMedicationforcardiovasculardiseaseduringpregnancy. Nat Rev Cardiol. 2015;12(12):718-29. 49. Ruys TP, Maggioni A, Johnson MR, Sliwa K, Tavazzi L, Schwerzmann M, et al. Cardiac medication during pregnancy, data from the ROPAC. Int J Cardiol. 2014;177(1):124-8. 50. Haas DM, Marsh DJ, Dang DT, Parker CB, Wing DA, Simhan HN, et al. Prescription and Other Medication Use in Pregnancy. Obstet Gynecol. 2018;131(5):789-98. 51. Canobbio MM, Warnes CA, Aboulhosn J, Connolly HM, Khanna A, Koos BJ. Management of Pregnancy in PatientsWith Complex Congenital Heart Disease. A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2017;135(8):e50-87. 52. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom- Lundqvist C, Cifkova R, De Bonis M, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-241. 53. Pariente G, Leibson T, Carls A, Adams. Webber T, Ito S, Koren G. Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med. 2016;13(11):e1002160. 54. Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of drugs in pregnancy. Semin Perinatol. 2015;39(7):512-9. 55. Parry E, Shields R, Turnbull AC. Transit time in the small intestine in pregnancy. J Obstet Gynaecol Br Commonw. 1970;77(10):900-1. 56. CarterBL,GarnettWR,PellockJM,StrattonMA,HowellJR.Effectofantacids on phenytoin bioavailability. Ther Drug Monit. 1981;3(4):333-40. 57. Anger GJ, Piquette-MillerM. Pharmacokinetic studies in pregnant women. Clin Pharmacol Ther. 2008;83(1):184–7. 58. Tracy TS, Venkataramanan R, Glover DD, Caritis SN; National Institute for Child Health and Human Development Network of Maternal- Fetal-Medicine Units. Temporal changes in drug metabolism (CYP1A2, CYP2D6 andCYP3AActivity) during pregnancy. Am J Obs Gynecol. 2005; 192(2):633-9. 59. Davison JM,DunlopW.Renalhemodynamicsandtubular functionnormal human pregnancy. Kidney Int. 1980;18(2):152-61. 60. Davison JM, Noble MC. Serial changes in 24 hour creatinine clearance during normal menstrual cycles and the first trimester of pregnancy. Br J Obstet Gynaecol. 1981;88(1):10-7. 61. Cheung KL, Lafayette RA. Renal physiology of pregnancy. Adv Chronic Kidney Dis. 2013; 20(3):209-14. 62. U. S. Food and Drug Administration. Milestones in U. S. Food and Drug Law History. 2018. [Internet]. [Cited in 2019 Feb 11]. Available from:// www.fda.gov//about-fda/fdas-evolving-regulatory-powers/milestones-us- food-and-drug-law-history 63. Brucker MC, King TL. The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule. J Midwifery Womens Health. 2017;62(3):308-16. 64. Clark SM, DunnHE, Hankins GD. A reviewof oral labetalol and nifedipine in mild to moderate hypertension in pregnancy. Semin Perinatol. 2015;39(7):548-55. 65. van Vliet EO, Schuit E, Heida KY, Opmeer BC, Kok M, Gyselaers W, et al. Nifedipine versus atosiban in the treatment of threatened preterm labour (Assessment of Perinatal Outcome after Specific Tocolysis in Early Labour: APOSTEL III-Trial). BMC Pregnancy Childbirth. 2014 Mar;14:93. 66. Bateman BT, Hernandez-Diaz S, Huybrechts KF, Palmsten K, Mogun H, Ecker JL, et al. Outpatient calcium–channel blockers and the risk of postpartumhaemorrhage: a cohort study. BJOG. 2013;120(13):1668-76; dicussion 1676-7. 67. Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet. 1982;1(8273):647-9. 68. Slim R, Ben Salem C, Hmouda H, Bouraoui K. Hepatotoxicity of alpha- methyldopa in pregnancy. J Clin Pharm Ther. 2010;35(3):361-3. 69. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta- analysis. BMJ. 2003;327(7421):955-60. 70. Buchanan ML, Easterling TR, Carr DB, Shen DD, Risler LJ, Nelson WL, et al. Clonidine pharmacokinetics in pregnancy. Drug Metab Dispos. 2009;37(4):702-5. 71. ACOGPractice Bulletin nº 203:Chronic Hypertension in Pregnancy. Obst Gynecol. 2019 Jan;133(1): e26-e50 72. Bowen ME, Ray WA, Arbogast PG, Ding H, Cooper WO. Increasing exposure to angiotensinconverting enzyme inhibitors in pregnancy. Am J Obstet Gynecol. 2008;198(3):291.e1-5. 73. Halpern D G, Weinberg C R, Pinnelas R, Mehta-Lee S, Economy KE, Valente AM. Use of Medication for Cardivascular Disease During Pregnancy. J Am Coll Cardiol. 2019;73(4):457-76. 74. Elkayam U, Goodwin TM. Adenosine therapy for supraventricular tachycardia during pregnancy. Am J Cardiol. 1995;75(7):521-3. 75. Matsubara S, Kuwata T, Mitsuhashi T. Adenosine for maternal supraventricular tachycardia and preterm delivery. J Obstet Gynaecol Can. 2011;33(8):794-5. 76. Bateman BT, Patorno E, Desai RJ, Seely EW, MogunH, Maeda A, et al. Late pregnancy beta blocker exposure and risks of neonatal hypoglycemia and bradycardia. Pediatrics. 2016;138(3). pii: e20160731. 77. Petersen KM, Jimenez-Solem E, Andersen JT, Petersen M, Brødbæk K, Køber L, et al. β -Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open. 2012;2(4):e001185. 78. Ersboll AS, Hedegaard M, Sondergaard L, Ersboll M, Johansen M. Treatment with oral betablockers during pregnancy complicated by maternal heart disease increases the risk of fetal growth restriction. BJOG. 2014; 121(5):618-26. 79. Lydakis C, Lip GY, Beevers M, Beevers DG. Atenolol and fetal growth in pregnanciescomplicatedbyhypertension.AmJHypertens.1999;12(6):541-7. 80. LipGY, BeeversM, Churchill D, Shaffer LM, Beevers DG. Effect of atenolol on birth weight. Am J Cardiol. 1997;79(10):1436-8. 931